INT215198

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 31
Disease Relevance 0.60
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
body 2
blood 1
Pit 1
Tg(GH)3Mi (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 62 96.56 Very High Very High Very High
anesthesia 31 74.72 Quite High
Disease Link Frequency Relevance Heat
Body Weight 93 86.48 High High
Decapitation 62 59.76 Quite High
Diabetes Mellitus 31 5.00 Very Low Very Low Very Low
Congenital Anomalies 31 5.00 Very Low Very Low Very Low
Endocrine Disease 31 5.00 Very Low Very Low Very Low
Obesity 31 5.00 Very Low Very Low Very Low
Disease 31 5.00 Very Low Very Low Very Low
Infertility 31 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fig. 2Cumulative release of hGH from DS 12 (closed squares, open squares), and 20 (closed triangles, open triangles) microspheres.
Localization (release) of hGH
1) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.05 Pain Relevance 0
For both batches, near zero-order release of hGH was observed for 9 days.
Localization (release) of hGH
2) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Apparently, both free hGH and hGH released from the microspheres evoked an immune response in these mice.
Localization (released) of hGH
3) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
The values are the average of two independent measurements and deviated less than 15%.Fig. 4Cumulative release of hGH from dex-HEMA microspheres (DS 16, initial water content 50%, initial protein loading) used in the clinical study (CTM, Table II).
Localization (release) of hGH
4) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
It is known that PEG and dextran can cause precipitation of hGH (6,27,37).
Localization (precipitation) of hGH
5) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Fig. 3Cumulative release of hGH from dex-HEMA microsphere (DS 16, initial water content 50%, initial protein loading 10% w/w) batches prepared without homogenization (ATM1, Table II; closed squares) and with homogenization of the emulsion prior to polymerization (ATM2, Table II; closed triangles).
Localization (release) of hGH
6) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
The results in Table I show that the time to release 90% of hGH decreased with increasing KPS concentration (e.g. compare formulation 8,9).
Localization (release) of hGH
7) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.07 Pain Relevance 0
Briefly, from the in vitro release data, the amount of hGH released subcutaneously per unit of time was calculated.
Localization (released) of hGH
8) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0.06
Figure 2 shows that hGH was released with almost zero order kinetics from dex-HEMA microspheres for 5–15 days, dependent on the formulation.
Localization (released) of hGH
9) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.09 Pain Relevance 0.06
This figure also shows that the time to release more than 90% of hGH increased with an increasing DS and decreasing protein loading, which is consistent with previous observations (18,26).
Localization (release) of hGH
10) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.08 Pain Relevance 0.03
Fig. 6a demonstrates that there is a good correlation between the amount of released hGH and the pharmacodynamic effects as the increase in body length almost perfectly follows the in vitro release curves.
Localization (released) of hGH in body
11) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
The ED50 for the binding of 125I-hGH to antibodies in the serum was obtained at serum dilutions of approximately 200×, 800× and 1,200× for free hGH, hGH released from microspheres from ATM1 and ATM2 respectively.
Localization (released) of hGH
12) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Apparently, both free hGH and hGH released from the microspheres evoked an immune response in these mice.
Localization (released) of hGH
13) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Furthermore, Fig. 6b shows that hGH released from dex-HEMA microspheres is as effective as hGH administered via daily injections as there is no difference between growth response to a certain amount hGH administered by single daily injection of a solution of hGH and to the same amount of hGH released from either small microspheres (ATM2) or large microspheres (ATM1).
Localization (released) of hGH
14) Confidence 0.11 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Furthermore, Fig. 6b shows that hGH released from dex-HEMA microspheres is as effective as hGH administered via daily injections as there is no difference between growth response to a certain amount hGH administered by single daily injection of a solution of hGH and to the same amount of hGH released from either small microspheres (ATM2) or large microspheres (ATM1).
Localization (released) of hGH
15) Confidence 0.10 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
In Fig. 3, the cumulative release profiles of hGH from the ATM1 and ATM2 batches are shown.
Localization (release) of hGH
16) Confidence 0.10 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
1Where, A1 is the amount of hGH present subcutaneously, R(t) is the amount of hGH released from the microspheres per unit of time, ka is the absorption rate constant, B is the bioavailability of hGH.
Localization (released) of hGH associated with bioavailability
17) Confidence 0.10 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0.10
The average serum profiles IGF-1 and IGFBP-3 followed the average serum growth hormone profile well, which suggests the preservation of bioactivity of released hGH from microspheres.
Localization (released) of hGH
18) Confidence 0.10 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
In Fig. 6 the cumulative in vitro release of hGH (ATM1, ATM2) and the cumulative administered amount of hGH (control) are plotted against the observed pharmacodynamic effect (increase in body length).
Localization (release) of hGH in body
19) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
In a clinical setting, hGH serum concentrations were compared to the calculated theoretical serum concentrations, based on the in vitro release profile of hGH after a single subcutaneous injection with hGH loaded dextran microspheres.
Localization (release) of hGH
20) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox